Key Highlights

  • Genetic Signatures (ASX:GSS) and Microba Life Sciences (ASX:MAP) have agreed the principal commercial terms of a proposed merger, to be implemented via a Scheme of Arrangement
  • Microba shareholders will receive 0.654 new GSS shares for each Microba share held, resulting in Microba shareholders holding approximately 67 percent of the combined group and existing GSS shareholders holding approximately 33 percent
  • The combined group would report aggregate FY2026 Revenue of approximately $29.6 million and aggregate cash and term deposits of approximately $30 million as at 30 June 2026
  • The companies have identified a minimum of $2.5 million to $3.0 million in potential annualised gross cost synergies, though these remain preliminary estimates subject to further validation

Genetic Signatures Limited (ASX:GSS) and Microba Life Sciences Limited (ASX:MAP) announced on 22 September 2026 that the two companies have reached agreement on the principal commercial terms of a proposed merger. The announcement follows an earlier disclosure dated 26 August 2026 confirming that the two Australian diagnostics companies were in Merger discussions.

Under the terms agreed, it is intended that the proposed merger will be implemented through a Scheme of Arrangement under which Genetic Signatures will acquire 100 percent of Microba's Issued Shares and options. Microba shareholders will receive 0.654 new Genetic Signatures shares for each Microba share held, equating to the issue of approximately 469 million new Genetic Signatures shares, subject to finalisation. Microba option holders will receive equivalent Options in Genetic Signatures on the same 0.654 ratio.

Following implementation, Microba shareholders would hold approximately 67 percent of the enlarged Genetic Signatures group, described as the Combined Group, with existing Genetic Signatures shareholders holding approximately 33 percent. The Combined Group would remain listed on the ASX under the existing GSS code.

Transaction Structure and Financial Scale

The transaction is structured as an all-scrip deal, with the proposed merger to be funded entirely through the issue of Genetic Signatures securities. No cash consideration or new Acquisition financing has been contemplated as part of the arrangement.

On a combined basis, the two businesses reported approximately $29.6 million in aggregate FY2026 revenue, with Genetic Signatures and Microba each contributing $14.8 million individually. Combined cash and term deposits stood at approximately $30 million as at 30 June 2026, comprising $22.1 million from Genetic Signatures and $7.9 million from Microba. Combined net Assets were reported at $60.1 million, made up of $35.7 million from Genetic Signatures and $24.4 million from Microba. The Combined Group would employ approximately 149 people and serve customers across more than 30 countries.

The companies have undertaken preliminary analysis identifying at least $2.5 million to $3.0 million in potential annualised gross cost synergies, principally through consolidation of duplicated listed-company costs, rationalisation of overlapping corporate and administrative functions, and consolidation of infrastructure and professional services expenditure. The companies have explicitly characterised these synergies as estimates rather than committed savings, noting they remain subject to further validation, implementation planning and successful execution.

Strategic Rationale and Governance

The proposed merger is intended to combine Genetic Signatures' patented 3base technology-based molecular diagnostics platform, focused on rapid, targeted pathogen detection, with Microba's metagenomic testing capabilities in microbiome profiling. The companies indicated the combination is intended to broaden their offering across gastrointestinal and infectious disease diagnostics.

On the commercial side, the merger would bring together Genetic Signatures' established relationships with hospital and reference laboratories and its existing regulatory approvals across Australia, Canada, the European Union and the United Kingdom, with Microba's clinician network, its established United Kingdom operations, and its commercial relationships with pathology groups including Sonic Healthcare and SYNLAB.

Under the proposed governance arrangements, the Board of the merged entity will comprise six directors, with three nominated by Genetic Signatures and three by Microba. The final composition of the Board and senior management arrangements will be confirmed in definitive transaction documentation.

Process and Next Steps

The parties intend to execute a definitive Scheme Implementation Deed following Genetic Signatures Shareholder approval to proceed with the proposed merger. The proposed merger will not proceed to execution of a definitive Scheme Implementation Deed unless the required Genetic Signatures shareholder approval is obtained.

Genetic Signatures will seek shareholder approval at a forthcoming Extraordinary General Meeting, with a Notice of Meeting and Explanatory Memorandum to follow, providing further detail on the commercial terms, financial implications, ownership structure, risks and applicable approval requirements. Beyond Genetic Signatures shareholder approval, the proposed merger remains conditional on ASX confirmations, execution of a definitive Scheme Implementation Deed, completion of an independent expert process, ASIC approval of a scheme booklet, Court approval for convening scheme meetings, approval by the requisite majorities of Microba shareholders and option holders, and satisfaction of other regulatory conditions.

Genetic Signatures is being advised by AE Advisors as corporate adviser and Gadens as legal adviser. Microba is being advised by Latimer Partners as corporate adviser and Thomsons as legal adviser. Shareholders of both companies are not required to take any action at this stage.

Bottom Line

The agreement on commercial terms marks a defined step in a process that began with the companies' disclosure of merger discussions in late August 2026. The proposed combination would create a diagnostics group with a broader geographic footprint spanning Australia, the United Kingdom, Europe and the United States, and a combined product portfolio spanning gastrointestinal and infectious disease molecular diagnostics alongside microbiome testing. Completion remains contingent on a sequence of shareholder, regulatory and court approvals, with the Scheme Implementation Deed still to be finalised and executed.